About
Copy Link
Titles
Staff Affiliate - YNHH
Departments & Organizations
- All Institutions
- Yale Medicine
Board Certifications
Certified Nurse Anesthetist
- Certification Organization
- National Board of Certification and Recertification of Nurse Anesthesia
- Latest Certification Date
- 2004
- Original Certification Date
- 1996
Research
Copy Link
Research at a Glance
Yale Co-Authors
Frequent collaborators of Mary Ellen Dwyer's published research.
Publications Timeline
A big-picture view of Mary Ellen Dwyer's research output by year.
Kenneth B. Roberts, MD
Syed Bilgrami, MBBS
Veda Giri, MD
12Publications
1,438Citations
Publications
2026
NCCN Guidelines® Insights: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 2.2026.
Wierda W, Brown J, Abramson J, Awan F, Bociek G, Boyer D, Cortese M, Cripe L, D'Angelo C, Darnell E, Davis R, Eradat H, Esteghamat N, Fitzgerald L, Fletcher C, Gaballa S, Huntington S, Kahl B, Kamdar M, Kipps T, Ma S, Mosse C, Nakhoda S, Parikh S, Riedell P, Schorr A, Schuster S, Seshadri M, Shanafelt T, Siddiqi T, Sitlinger A, Thompson M, Ujjani C, Wagner-Johnston N, Woyach J, Dwyer M, Sundar H. NCCN Guidelines® Insights: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 2.2026. Journal Of The National Comprehensive Cancer Network 2026, 24: 68-80. PMID: 41825137, DOI: 10.6004/jnccn.2026.0012.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsConceptsUndetectable measurable residual diseaseRichter transformationHistological transformationTransformed DLBCLChronic lymphocytic leukemia/small lymphocytic lymphomaDiffuse large B-cell lymphomaLarge B-cell lymphomaBruton tyrosine kinase inhibitorTreatment of CLL/SLLMeasurable residual diseaseB-cell lymphomaNCCN Guidelines InsightsTyrosine kinase inhibitorsAppropriate treatment optionRandomized clinical trialsLisocabtagene maraleucelResidual diseaseLymphocytic lymphomaRefractory diseaseNCCN guidelinesClonal relationshipSurvival outcomesPoor prognosisCLL/SLLTreatment optionsNCCN Guidelines® Insights: Genetic/Familial High-Risk Assessment: Breast, Ovarian, Pancreatic, and Prostate, Version 2.2026.
Cheng H, Giri V, Goggins M, Yurgelun M, Karlan B, Norquist B, Daly M, Pal T, AlHilli Z, Arun B, Churpek J, Colonna S, Domchek S, Escobar M, Fejerman L, Friedman S, Hagemann A, Hendrix A, Huo D, Hutton M, Kassem N, Khan S, Kurian A, Laronga C, Mak J, Maxwell K, McDonnell K, Merajver S, Mersch J, Offit K, Plichta J, Rash D, Reiser G, Senter-Jamieson L, Shannon K, Welborn J, Wick M, Wood M, Darlow S, Diwan Z, Dwyer M. NCCN Guidelines® Insights: Genetic/Familial High-Risk Assessment: Breast, Ovarian, Pancreatic, and Prostate, Version 2.2026. Journal Of The National Comprehensive Cancer Network 2026, 24: 2-10. PMID: 41671423, DOI: 10.6004/jnccn.2026.0007.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsConceptsComprehensive careGenetic/Familial High-Risk AssessmentHealth care providersCare of individualsNCCN Clinical Practice GuidelinesRisk of breastProstate cancerClinical practice guidelinesCancer risk assessmentComprehensive care of individualsGenetic counseling/testingCare providersHereditary breastCare strategiesNonepithelial ovarian cancersHigh-risk assessmentNCCN Guidelines InsightsP/LP variantsPractice guidelinesGenetic testingGenetic counselingNCCN guidelinesPancreas cancerOvarian cancerProstate
2025
NCCN Guidelines® Insights: B-Cell Lymphomas 3.2025.
Zelenetz A, Gordon L, Abramson J, Advani R, Andreadis B, Bartlett N, Budde L, Caimi P, Chang J, Christian B, DeVos S, Dholaria B, Fayad L, Habermann T, Hamid M, Hernandez-Ilizaliturri F, Hu B, Karimi Y, Kelsey C, King R, Kline J, Krivacic S, LaCasce A, Landsburg D, Lim M, Messmer M, Rabinovitch R, Ramakrishnan P, Reid E, Roberts K, Saeed H, Saito N, Smith S, Swinnen L, Tuscano J, Vose J, Dwyer M, Sundar H. NCCN Guidelines® Insights: B-Cell Lymphomas 3.2025. Journal Of The National Comprehensive Cancer Network 2025, 23 PMID: 41067277, DOI: 10.6004/jnccn.2025.0048.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsConceptsDiffuse large B-cell lymphomaMantle cell lymphomaB-cell lymphomaBruton's tyrosine kinaseFollicular lymphomaTreatment landscapeRelapsed/refractory diffuse large B-cell lymphomaClassic mantle cell lymphomaLarge B-cell lymphomaInhibitor-based regimensRelapsed/refractory follicular lymphomaTreatment of FLNCCN Guidelines InsightsEffective treatment optionAntibody-drug conjugatesCell lymphomaNCCN guidelinesTargeted therapyTreatment optionsB cellsLymphomaClinical trialsBispecific antibodiesMonoclonal antibodiesTyrosine kinase
2024
Genetic/Familial High-Risk Assessment: Colorectal, Endometrial, and Gastric, Version 3.2024, NCCN Clinical Practice Guidelines In Oncology.
Hodan R, Gupta S, Weiss J, Axell L, Burke C, Chen L, Chung D, Clayback K, Felder S, Foda Z, Giardiello F, Grady W, Gustafson S, Hagemann A, Hall M, Hampel H, Idos G, Joseph N, Kassem N, Katona B, Kelly K, Kieber-Emmons A, Kupfer S, Lang K, Llor X, Markowitz A, Prats M, Niell-Swiller M, Outlaw D, Pirzadeh-Miller S, Samadder N, Shibata D, Stanich P, Swanson B, Szymaniak B, Welborn J, Wiesner G, Yurgelun M, Dwyer M, Darlow S, Diwan Z. Genetic/Familial High-Risk Assessment: Colorectal, Endometrial, and Gastric, Version 3.2024, NCCN Clinical Practice Guidelines In Oncology. Journal Of The National Comprehensive Cancer Network 2024, 22: 695-711. PMID: 39689429, DOI: 10.6004/jnccn.2024.0061.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsConceptsMultigene panel testingPathogenic/likely pathogenic variantsGenetic/Familial High-Risk AssessmentColon cancer screeningColon cancer riskHigh risk of cancerNCCN Clinical Practice GuidelinesClinical practice guidelinesRisk of cancerPanel testingHigh riskPathogenic variantsPeutz-Jeghers syndromeLynch syndromeCancer screeningDe-implementationCancer riskEndometrial cancerPTEN hamartoma tumor syndromeHigh-risk assessmentPractice guidelinesHamartoma tumor syndromePeutz-JeghersNCCN guidelinesCHEK2Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 2.2024, NCCN Clinical Practice Guidelines in Oncology
Wierda W, Brown J, Abramson J, Awan F, Bilgrami S, Bociek G, Brander D, Cortese M, Cripe L, Davis R, Eradat H, Fakhri B, Fletcher C, Gaballa S, Hamid M, Hill B, Kaesberg P, Kahl B, Kamdar M, Kipps T, Ma S, Mosse C, Nakhoda S, Parikh S, Schorr A, Schuster S, Seshadri M, Siddiqi T, Stephens D, Thompson M, Ujjani C, Valdez R, Wagner-Johnston N, Woyach J, Sundar H, Dwyer M. Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 2.2024, NCCN Clinical Practice Guidelines in Oncology. Journal Of The National Comprehensive Cancer Network 2024, 22: 175-204. PMID: 38626800, DOI: 10.6004/jnccn.2024.0018.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsConceptsSmall lymphocytic lymphomaChronic lymphocytic leukemiaPredictor of improved survivalUndetectable minimal residual diseaseImmunoglobulin heavy chain variable region mutational statusMinimal residual diseaseManagement of patientsSelection of treatmentRelapsed/refractory CLL/SLLLymphocytic lymphomaResidual diseaseCombination regimensTP53 mutationsMutation statusPerformance statusLymphocytic leukemiaNCCN guidelinesPatient agePrognostic implicationsToxicity profileDisease stageComorbid conditionsPatientsCLL/SLLCytogenetic variability
2023
NCCN Guidelines® Insights: B-Cell Lymphomas, Version 6.2023.
Zelenetz A, Gordon L, Abramson J, Advani R, Andreadis B, Bartlett N, Budde L, Caimi P, Chang J, Christian B, DeVos S, Dholaria B, Fayad L, Habermann T, Hamid M, Hernandez-Ilizaliturri F, Hu B, Kaminski M, Karimi Y, Kelsey C, King R, Krivacic S, LaCasce A, Lim M, Messmer M, Narkhede M, Rabinovitch R, Ramakrishnan P, Reid E, Roberts K, Saeed H, Smith S, Svoboda J, Swinnen L, Tuscano J, Vose J, Dwyer M, Sundar H. NCCN Guidelines® Insights: B-Cell Lymphomas, Version 6.2023. Journal Of The National Comprehensive Cancer Network 2023, 21: 1118-1131. PMID: 37935098, DOI: 10.6004/jnccn.2023.0057.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsConceptsB-cell lymphomaMantle cell lymphomaCAR T-cell therapyT-cell therapyTyrosine kinase inhibitorsFollicular lymphomaNCCN guidelinesAnti-CD19 CAR T-cell therapyRefractory B-cell lymphomaTreatment of FLBispecific T-cell engagersBruton tyrosine kinase inhibitorsLarge B-cell lymphomaNCCN Guidelines InsightsRefractory follicular lymphomaNovel immunotherapeutic approachesRelapsed Follicular LymphomaT-cell engagersTreatment landscapeImmunotherapeutic approachesFrontline settingTreatment optionsCell lymphomaLymphomaTherapy
2018
NCCN Guidelines Insights: Bladder Cancer, Version 5.2018.
Flaig T, Spiess P, Agarwal N, Bangs R, Boorjian S, Buyyounouski M, Downs T, Efstathiou J, Friedlander T, Greenberg R, Guru K, Hahn N, Herr H, Hoimes C, Inman B, Jimbo M, Kader A, Lele S, Meeks J, Michalski J, Montgomery J, Pagliaro L, Pal S, Patterson A, Petrylak D, Plimack E, Pohar K, Porter M, Preston M, Sexton W, Siefker-Radtke A, Tward J, Wile G, Johnson-Chilla A, Dwyer M, Gurski L. NCCN Guidelines Insights: Bladder Cancer, Version 5.2018. Journal Of The National Comprehensive Cancer Network 2018, 16: 1041-1053. PMID: 30181416, DOI: 10.6004/jnccn.2018.0072.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsMeSH KeywordsAdministration, IntravesicalAftercareBCG VaccineChemotherapy, AdjuvantCystectomyHumansLymphatic MetastasisMedical OncologyNeoadjuvant TherapyNeoplasm StagingOrgan Sparing TreatmentsPatient SelectionQuality of LifeRadiotherapy, AdjuvantRandomized Controlled Trials as TopicSocieties, MedicalTreatment OutcomeUnited StatesUrinary Bladder NeoplasmsConceptsBladder cancerTreatment of muscle-invasive bladder cancerImmune checkpoint inhibitor therapyMuscle-invasive bladder cancerNCCN Clinical Practice GuidelinesFollow-up of patientsAJCC Cancer Staging ManualCheckpoint inhibitor therapyCancer Staging ManualNCCN Guidelines InsightsClinical practice guidelinesMetastatic diseaseInhibitor therapyStaging ManualTreatment optionsFollow-upCancerBladderPractice guidelinesPatientsNCCNTreatmentAJCCTherapyGuidelinesNCCN Guidelines Insights: Colorectal Cancer Screening, Version 1.2018.
Provenzale D, Gupta S, Ahnen D, Markowitz A, Chung D, Mayer R, Regenbogen S, Blanco A, Bray T, Cooper G, Early D, Ford J, Giardiello F, Grady W, Hall M, Halverson A, Hamilton S, Hampel H, Klapman J, Larson D, Lazenby A, Llor X, Lynch P, Mikkelson J, Ness R, Slavin T, Sugandha S, Weiss J, Dwyer M, Ogba N. NCCN Guidelines Insights: Colorectal Cancer Screening, Version 1.2018. Journal Of The National Comprehensive Cancer Network 2018, 16: 939-949. PMID: 30099370, DOI: 10.6004/jnccn.2018.0067.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsMeSH KeywordsAge FactorsAgedAged, 80 and overBiomarkers, TumorColonoscopyColorectal NeoplasmsDNA, NeoplasmEarly Detection of CancerFecesHumansImmunochemistryMass ScreeningMedical OncologyMiddle AgedOccult BloodRandomized Controlled Trials as TopicSeptinsSocieties, MedicalTime FactorsTomography, X-Ray ComputedUnited StatesConceptsColorectal cancerNCCN guidelinesRecommended screening strategySporadic colorectal cancerAverage-riskNCCN panelScreening modalitiesNCCN Guidelines InsightsScreening individualsIncreased-riskScreening strategiesNCCNGuidelinesRelevant dataIndividualsColorectalModalitiesPrimary focusScreeningRecommendationsReview commentsCancerFocusNCCN Guidelines Insights: T-Cell Lymphomas, Version 2.2018.
Horwitz S, Ansell S, Ai W, Barnes J, Barta S, Choi M, Clemens M, Dogan A, Greer J, Halwani A, Haverkos B, Hoppe R, Jacobsen E, Jagadeesh D, Kim Y, Lunning M, Mehta A, Mehta-Shah N, Oki Y, Olsen E, Pro B, Rajguru S, Shanbhag S, Shustov A, Sokol L, Torka P, Wilcox R, William B, Zain J, Dwyer M, Sundar H. NCCN Guidelines Insights: T-Cell Lymphomas, Version 2.2018. Journal Of The National Comprehensive Cancer Network 2018, 16: 123-135. PMID: 29439173, DOI: 10.6004/jnccn.2018.0007.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsConceptsExtranodal NK/T-cell lymphomaNK/T-cell lymphomaNatural killer (NK)/T-cell lymphomaSubtype of non-Hodgkin lymphomaNon-Hodgkin's lymphomaT-cell lymphomaNCCN Guidelines InsightsUpper aerodigestive tractManagement of patientsNasal typeNK/T-cellRare malignancyStandard therapyNCCN guidelinesAerodigestive tractT cellsLymphomaRandomized trialsPatientsNCCNMalignancyRegimensTherapySubtypesDiagnosis
2017
NCCN Guidelines Insights: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 1.2017.
Wierda W, Zelenetz A, Gordon L, Abramson J, Advani R, Andreadis C, Bartlett N, Byrd J, Caimi P, Fayad L, Fisher R, Glenn M, Habermann T, Harris N, Hernandez-Ilizaliturri F, Hoppe R, Horwitz S, Kaminski M, Kelsey C, Kim Y, Krivacic S, LaCasce A, Martin M, Nademanee A, Porcu P, Press O, Rabinovitch R, Reddy N, Reid E, Roberts K, Saad A, Snyder E, Sokol L, Swinnen L, Vose J, Yahalom J, Dwyer M, Sundar H. NCCN Guidelines Insights: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 1.2017. Journal Of The National Comprehensive Cancer Network 2017, 15: 293-311. PMID: 28275031, DOI: 10.6004/jnccn.2017.0030.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsConceptsSmall lymphocytic lymphomaChronic lymphocytic leukemiaTreatment of patientsNCCN Clinical Practice GuidelinesCD20 monoclonal antibodyNCCN Guidelines InsightsClinical practice guidelinesRelapsed/refractory CLL/SLLChemoimmunotherapy regimensLymphocytic lymphomaCritical signaling pathwaysLymphocytic leukemiaSmall molecule inhibitorsCLL/SLLBcl-2 familyBcl-2Monoclonal antibodiesMolecule inhibitorsSignaling pathwayPractice guidelinesPatientsNCCNTreatmentLymphomaRegimens
Academic Achievements & Community Involvement
Copy Link
Get In Touch
Copy Link